Showing results (131-140 of 187) with videos related to

Sort By:
Pageof 19
Rheumatology (Oxford, England)|May 13, 2025
Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from FIRST registrySatoshi Kubo, Yusuke Miyazaki, Hiroaki Tanaka, et al.
Journal of Biomedical Materials Research. Part B, Applied Biomaterials|January 7, 2011
Increased survival of free fat grafts and vascularization in rats with local delivery of fragmin/protamine microparticles containing FGF-2 (F/P MP-F)Shinichiro Nakamura, Masayuki Ishihara, Megumi Takikawa, et al.
Rheumatology (Oxford, England)|September 1, 2018
Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathiesSatoshi Kubo, Yasuyuki Todoroki, Shingo Nakayamada, et al.
Rheumatology (Oxford, England)|June 18, 2024
Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registryYusuke Miyazaki, Shingo Nakayamada, Hiroaki Tanaka, et al.
International Journal of Rheumatic Diseases|February 6, 2020
Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosisSatoshi Kubo, Anne Sofie Siebuhr, Anne-C Bay-Jensen, et al.
Communications Biology|February 5, 2021
Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibitionShinya Mimasu, Hiroaki Yamagishi, Satoshi Kubo, et al.
Arthritis Research & Therapy|March 17, 2021
Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitisMasanobu Ueno, Ippei Miyagawa, Kazuhisa Nakano, et al.
Arthritis Research & Therapy|June 2, 2021
Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME studyYusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, et al.
Bioorganic & Medicinal Chemistry|February 14, 2019
Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitorToshihiro Hamajima, Fumie Takahashi, Koji Kato, et al.
Pageof 19